A promising new drug could turn the tide against HIV. But it’s hard to find where it’s needed most

In the bustling red light district of Mbarara, Uganda, Lisa Mutoni, a sex worker, stands at the threshold of her room, a determined look on her face. She insists on using condoms with her clients to protect herself from HIV and other sexually transmitted infections. Yet, vulnerability looms large as some clients attempt to remove or tear the condom during intercourse. For Mutoni, the stakes are high. She relies on HIV-prevention medication known as PrEP, but a new drug called lenacapavir offers a beacon of hope — if only she could access it.

What Happened

Lenacapavir, developed by Gilead Sciences, has shown promising results in clinical trials, providing nearly complete protection from HIV with just two injections per year. This long-lasting effect could be revolutionary for individuals like Mutoni, who may not always have the means or consistency to take daily pills. "If you know that you have that injection for six months, you feel like you are safe," she explains. However, the reality is stark: every time Mutoni seeks lenacapavir, she is met with disappointment. "They tell me that it is finished," she laments.

The disparity between the drug's potential and its availability highlights a critical gap in the fight against HIV. Health experts, including Andrew Hill from the University of Liverpool, have raised concerns about the slow rollout of lenacapavir. "The rate of growth isn’t fast enough. We need to be getting to the millions pretty soon," he warns. In Uganda, where approximately 10% of the adult population lives with HIV, the urgent need for effective prevention methods has never been clearer.

Community Impact

The implications of lenacapavir's limited availability extend beyond individual health. In Mbarara, where transactional sex is prevalent, the drug could significantly reduce new HIV infections. Julius Bampe, a polygamous man, faced a harrowing moment when his younger wife tested positive for HIV. Despite her immediate treatment, Bampe's attempt to secure lenacapavir for himself was thwarted by supply shortages. "When I got here, they said that is what they would have given me, but they said they didn’t have enough doses for everyone," he recounted.

The local health center received a mere 40 doses in April, initially designated for pregnant women at risk of HIV. As the situation evolved, the guidelines expanded to include couples like Bampe and sex workers, but the limited supply remained a pressing issue. Tarsisio Biryeija, a nursing officer at Mbarara Health Centre IV, noted that another batch of 70 doses was consumed within ten days, underscoring the overwhelming demand.

Voices from the Ground

Community leaders like Immaculate Nyamwija, founder of Action for Improved Health and Wealth, work tirelessly to support women in Mbarara who face discrimination and stigma. Nyamwija provides counseling and essential health services, including access to condoms and HIV support. Yet, she acknowledges the challenges posed by the drug shortage. "It is a challenge, because the demand is high and the doses are few," she states. The community's hopes for lenacapavir are palpable, as many would prefer a long-lasting solution over daily medication.

The Broader HIV Epidemic in Uganda

Understanding the context of HIV in Uganda is crucial. The country has made significant strides in reducing its HIV prevalence over the past three decades, yet challenges remain, particularly in urban centers like Mbarara. The city is known for its vibrant nightlife and economic activities, which unfortunately also include transactional sex. This socio-economic backdrop contributes to the ongoing spread of HIV, particularly among marginalized groups such as sex workers and their clients.

Local health officials have emphasized the importance of targeted interventions to reach high-risk populations. Programs that offer education, testing, and treatment are vital, yet they often lack the resources needed to be effective. The introduction of lenacapavir could complement these efforts, but only if it is made widely available.

Global Response

On a broader scale, the recent tentative approval by the U.S. Food and Drug Administration (FDA) for a generic version of lenacapavir may signal a turning point. This generic option could facilitate production and distribution to 120 low-income countries at a drastically reduced cost of roughly $40 a year, compared to the staggering U.S. list price of $28,218. The Global Fund aims to provide lenacapavir to 3 million people by the end of 2028, a goal that could change the landscape of HIV prevention.

However, advocacy groups like Doctors Without Borders (MSF) argue that this initiative falls short. MSF's Melissa Barber criticized Gilead's distribution strategy, stating, "Gilead says it wants to end the HIV epidemic ‘for everyone, everywhere,’ but its actions say otherwise." The call for more affordable doses and direct sales to organizations like MSF reflects the urgent need for a more equitable approach to healthcare access.

Looking Forward

As the promise of lenacapavir hangs in the balance, the community of Mbarara remains resilient. The fight against HIV is not just about medication; it's about education, access, and breaking the stigma surrounding the disease. Local health initiatives are crucial in raising awareness about prevention methods and providing support for those affected by HIV.

For individuals like Lisa Mutoni, the hope for lenacapavir represents more than just a drug; it symbolizes a chance for a healthier future. "Who would not wish to take (lenacapavir) for six months?" she asks, echoing the sentiments of many in her community. The road ahead may be challenging, but with increased advocacy and global attention, there is potential for meaningful change in the fight against HIV.

The Role of Community Health Workers

Community health workers play a pivotal role in bridging the gap between healthcare services and marginalized populations. In Mbarara, these workers often serve as the first point of contact for individuals seeking HIV prevention and treatment. They provide education on safe sex practices, distribute condoms, and facilitate access to healthcare services, including testing and treatment options. Their presence is vital in fostering trust within the community and encouraging individuals to seek help without fear of stigma.

As the demand for lenacapavir grows, empowering community health workers with the resources and training they need will be essential. They can advocate for more equitable distribution of the drug and ensure that those most at risk are prioritized. This grassroots approach not only addresses immediate health needs but also contributes to a broader cultural shift toward acceptance and understanding of HIV.

Advocacy and Policy Changes

The ongoing struggle for access to lenacapavir highlights the need for advocacy at multiple levels. Local organizations, health professionals, and affected individuals must come together to push for policy changes that prioritize HIV prevention and treatment. This includes lobbying for increased funding, improved supply chains, and more inclusive healthcare policies that recognize the unique needs of vulnerable populations.

As the global health community rallies around the goal of ending the HIV epidemic, it is crucial that the voices of those most affected are heard. Their experiences and needs should inform the policies that shape healthcare access and delivery. With concerted effort and collaboration, there is hope for a future where effective HIV prevention methods like lenacapavir are accessible to all who need them.